Uhlén S, Muceniece R, Rangel N, Tiger G, Wikberg J E
Department of Pharmacology, Umeå University, Sweden.
Pharmacol Toxicol. 1995 Jun;76(6):353-64. doi: 10.1111/j.1600-0773.1995.tb00161.x.
Simultaneous computer modelling of control and guanfacine-masked [3H]-MK 912 saturation curves as well as guanfacine competition curves revealed that both alpha 2A- and alpha 2C-adrenoceptor subtypes were present in the guinea pig cerebral cortex. The Kd value of [3H]-MK 912 determined for the alpha 2A-subtype was 403 pM and for the alpha 2C-subtype 79.8 pM; the receptor sites showing capacities 172 and 19.5 fmol/mg protein, respectively. The Kds of guanfacine were 20 and 880 nM for the alpha 2A- and alpha 2C-adrenoceptor, respectively. In the guinea pig kidney [3H]-MK 912 bound to a single saturable site with Kd 8.34 nM and capacity 285 fmol/mg protein, the site showing pharmacological properties like an alpha 2B-adrenoceptor. Binding constants of 22 compounds for the three guinea pig alpha 2-adrenoceptor subtypes were determined by computer modelling competition curves using for the cerebral cortex a "3-curve assay", for the kidney an "1-curve assay", and using [3H]-MK 912 as labelled ligand. Of the tested drugs guanfacine and BRL 44408 were found to be clearly alpha 2A-selective, Spiroxatrine, yohimbine, rauwolscine and WB 4101, as well as [3H]-MK 912 itself, were found to be alpha 2C-selective. The most selective compounds for alpha 2B-adrenoceptors, when compared to alpha 2A-adrenoceptors, were ARC 239 and prazosin. In the guinea pig kidney [3H]-p-aminoclonidine bound to alpha as well as to non-adrenergic imidazoline sites. The alpha 2-adrenoceptors could be completely blocked using 10 microM (-)-adrenaline without the non-adrenergic sites being affected. During these conditions the analysis of combined saturation and competition studies using labelled and unlabelled p-aminoclonidine with computer modelling revealed that the ligand labelled two different sites with Kds of 310 and 47,000 nM, respectively. Competition curves of 16 compounds for the non-adrenergic [3H]-p-aminoclonidine sites were shallow and resolved into two-site fits. For the high affinity [3H]-p-aminoclonidine site the highest affinities were shown by 1-medetomidine, UK-14,304, guanabenz and detomidine; the Kds of these drugs ranging 26-72 nM. All drugs tested showed low but varying affinities for the low affinity [3H]-p-aminoclonidine site. These data indicated that the [3H]-p-aminoclonidine binding sites of the guinea pig kidney are grossly different from the [3H]-idazoxan binding I2-receptors previously demonstrated also to be present in the guinea pig kidney.
同时对对照和胍法辛掩盖的[³H]-MK 912饱和曲线以及胍法辛竞争曲线进行计算机建模,结果显示豚鼠大脑皮层中同时存在α₂A-和α₂C-肾上腺素能受体亚型。针对α₂A-亚型测定的[³H]-MK 912的Kd值为403 pM,α₂C-亚型为79.8 pM;受体位点的容量分别为172和19.5 fmol/mg蛋白质。胍法辛对α₂A-和α₂C-肾上腺素能受体的Kd值分别为20和880 nM。在豚鼠肾脏中,[³H]-MK 912与单一可饱和位点结合,Kd为8.34 nM,容量为285 fmol/mg蛋白质,该位点表现出类似α₂B-肾上腺素能受体的药理学特性。通过计算机建模竞争曲线,使用“3曲线分析法”对大脑皮层进行研究,使用“1曲线分析法”对肾脏进行研究,并使用[³H]-MK 912作为标记配体,测定了22种化合物对三种豚鼠α₂-肾上腺素能受体亚型的结合常数。在所测试的药物中,发现胍法辛和BRL 44408具有明显的α₂A选择性,螺沙群、育亨宾、萝芙辛和WB 4101以及[³H]-MK 912本身具有α₂C选择性。与α₂A-肾上腺素能受体相比,对α₂B-肾上腺素能受体最具选择性的化合物是ARC 239和哌唑嗪。在豚鼠肾脏中,[³H]-对氨基可乐定与α-以及非肾上腺素能咪唑啉位点结合。使用10 μM(-)-肾上腺素可完全阻断α₂-肾上腺素能受体,而不影响非肾上腺素能位点。在这些条件下,使用标记和未标记的对氨基可乐定进行联合饱和与竞争研究,并通过计算机建模分析,结果显示该配体标记了两个不同的位点,Kd分别为310和47,000 nM。16种化合物对非肾上腺素能[³H]-对氨基可乐定位点的竞争曲线较浅,可解析为双位点拟合。对于高亲和力的[³H]-对氨基可乐定位点,1-美托咪定、UK-14,304、胍那苄和右美托咪定表现出最高亲和力;这些药物的Kd值在26 - 72 nM范围内。所有测试药物对低亲和力的[³H]-对氨基可乐定位点均表现出低但不同的亲和力。这些数据表明,豚鼠肾脏中[³H]-对氨基可乐定的结合位点与先前在豚鼠肾脏中也已证明存在的[³H]-咪唑克生结合的I₂-受体有很大不同。